CYCC.P Stock Overview
A clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Cyclacel Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.45 |
| 52 Week High | US$22.20 |
| 52 Week Low | US$5.25 |
| Beta | 0.59 |
| 11 Month Change | 26.00% |
| 3 Month Change | -49.71% |
| 1 Year Change | -25.59% |
| 33 Year Change | -1.55% |
| 5 Year Change | 61.26% |
| Change since IPO | -14.09% |
Recent News & Updates
Recent updates
Shareholder Returns
| CYCC.P | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 26.2% | -0.3% | 0.3% |
| 1Y | -25.6% | 11.0% | 22.5% |
Return vs Industry: CYCC.P underperformed the US Biotechs industry which returned 11% over the past year.
Return vs Market: CYCC.P underperformed the US Market which returned 22.5% over the past year.
Price Volatility
| CYCC.P volatility | |
|---|---|
| CYCC.P Average Weekly Movement | 29.6% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: CYCC.P's share price has been volatile over the past 3 months.
Volatility Over Time: CYCC.P's weekly volatility has increased from 20% to 30% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | n/a | Spiro Rombotis | www.cyclacel.com |
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company’s lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias.
Cyclacel Pharmaceuticals, Inc. Fundamentals Summary
| CYCC.P fundamental statistics | |
|---|---|
| Market cap | US$2.49m |
| Earnings (TTM) | -US$19.85m |
| Revenue (TTM) | US$449.00k |
5.3x
P/S Ratio-0.1x
P/E RatioIs CYCC.P overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CYCC.P income statement (TTM) | |
|---|---|
| Revenue | US$449.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$449.00k |
| Other Expenses | US$20.30m |
| Earnings | -US$19.85m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -13.56 |
| Gross Margin | 100.00% |
| Net Profit Margin | -4,420.49% |
| Debt/Equity Ratio | 0% |
How did CYCC.P perform over the long term?
See historical performance and comparison